{
  "source": "PA-Med-Nec-Alhemo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2369-1\nProgram Prior Authorization/Medical Necessity\nMedication Alhemo® (concizumab-mtci)\nP&T Approval Date 3/2025\nEffective Date 6/1/2025\n1. Background:\nAlhemo (concizumab-mtci) is a tissue factor pathway inhibitor (TFPI) antagonist indicated for\nroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric\npatients 12 years of age and older with:\n• hemophilia A (congenital factor VIII deficiency) with FVIII inhibitors\n• hemophilia B (congenital factor IX deficiency) with FIX inhibitors\n2. Coverage Criteriaa:\nA. Hemophilia A With Inhibitors\n1. Initial Authorization\na. Alhemo will be approved based on all of the following criteria:\n(1) Diagnosis of hemophilia A\n-AND-\n(2) Patient is 12 years of age or older\n-AND-\n(3) Patient has developed high-titer factor VIII inhibitors (≥ 5 Bethesda units [BU])\n-AND-\n(4) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)\nAuthorization of therapy will be issued for 12 months.\n2. Reauthorization\na. Alhemo will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Alhemo therapy\nAuthorization will be issued for 12 months.\nB. Hemophilia B With Inhibitors\n© 2025 UnitedHealthcare Services Inc.\n1\n1. Initial Authorization\na. Alhemo will be approved based on all of the following criteria:\n(1) Diagnosis of hemophilia B\n-AND-\n(1) Patient is 12 years of age or older\n-AND-\n(2) Patient has developed high-titer factor IX inhibitors (≥ 5 Bethesda units [BU])\n-AND-\n(3) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)\nAuthorization of therapy will be issued for 12 months.\n2. Reauthorization\na. Alhemo will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Alhemo therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member spe",
    "terion:\n(1) Documentation of positive clinical response to Alhemo therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Alhemo® [package insert]. Plainsboro, NJ: Novo Nordisk Inc., December 2024.\n2. Matsushita T, Shapiro A, Abraham A, et al. Phase 3 Trial of Concizumab in Hemophilia with\nInhibitors. N Engl J Med. 2023;389(9):783-794. doi:10.1056/NEJMoa2216455\n© 2025 UnitedHealthcare Services Inc.\n2\nProgram Prior Authorization/Medical Necessity - Alhemo (concizumab-mtci)\nChange Control\n3/2025 New program.\n© 2025 UnitedHealthcare Services Inc.\n3"
  ]
}